Provided by Tiger Fintech (Singapore) Pte. Ltd.

Editas Medicine

1.61
-0.0450-2.73%
Volume:808.58K
Turnover:1.31M
Market Cap:134.35M
PE:-0.56
High:1.66
Open:1.66
Low:1.57
Close:1.65
Loading ...

Editas Medicine (EDIT) Gets a Sell from Bank of America Securities

TIPRANKS
·
30 Apr

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
30 Apr

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

GlobeNewswire
·
29 Apr

Editas Medicine Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
28 Apr

HC Wainwright Initiates Coverage on Editas Medicine With Buy Rating, $3 Price Target

MT Newswires Live
·
28 Apr

Editas Medicine, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $3

THOMSON REUTERS
·
28 Apr

Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report?

Zacks
·
04 Apr

Dyne Therapeutics Names Erick Lucera as CFO

MT Newswires Live
·
21 Mar

Dyne Therapeutics Names Editas Medicine's Lucera as CFO

Dow Jones
·
21 Mar

BRIEF-Editas Medicine Announces Chief Financial Officer Transition

Reuters
·
21 Mar

Editas Medicine CFO Erick Lucera to step down, Amy Parison to succeed

TIPRANKS
·
21 Mar

Editas Medicine Announces Chief Financial Officer Transition

THOMSON REUTERS
·
21 Mar

Editas Medicine Inc - Amy Parison Appointed as Editas CFO

THOMSON REUTERS
·
21 Mar

Press Release: Editas Medicine Announces Chief Financial Officer Transition

Dow Jones
·
21 Mar

Cautious Hold Rating on Editas Medicine Amid Early Development Stage and Long-Term Milestones

TIPRANKS
·
15 Mar

Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely

Simply Wall St.
·
13 Mar

Is Lithia Motors Inc. (NYSE:LAD) Among the Most Promising Car Stocks According to Hedge Funds?

Insider Monkey
·
12 Mar

Buy Rating for Editas Medicine Driven by Promising Preclinical Advances and Strong Financial Position

TIPRANKS
·
07 Mar

Editas Medicine Inc.’s Stock Volatility: Key Risks and Investor Considerations

TIPRANKS
·
07 Mar

Analysts’ Top Healthcare Picks: Editas Medicine (EDIT), Viking Therapeutics (VKTX)

TIPRANKS
·
07 Mar